[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"news-aggregator-insider-selling-cytokinetics-n33019a569b-fb3c-7a20-89b9-c9b12445d35a":3},{"id":4,"timestamp":5,"title":6,"content":7,"link":8,"preview":9,"tags":10,"predictedTags":11,"showTags":12,"source":13,"reactions":14,"selfReactions":15,"logo":16,"sourceId":17,"sourceUserId":18,"asset":19,"tagsCategories":20,"totalComments":21,"lang":22,"unique_views_count":23,"enrichStatus":19,"triageKind":18,"triageImportance":18,"expandEligible":18,"summarizeEligible":18,"eventEligible":18,"eventType":18,"eventAction":18},"insider-selling-cytokinetics-n33019a569b-fb3c-7a20-89b9-c9b12445d35a","1762389442000","Insider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells 2,295 Shares of Stock","Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Fady Ibraham Malik sold 2,295 shares of the firm's stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $59.55, for a total value of $136,667.25. Following the completion of the sale, the executive vice president directly owned 140,610 shares in the company, valued at $8,373,325.50. This trade represents a 1.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.","https://www.marketbeat.com/instant-alerts/insider-selling-cytokinetics-nasdaqcytk-evp-sells-2295-shares-of-stock-2025-11-04/","https://www.marketbeat.com/images/marketbeat-logo-1200-1200.jpg?v=1","[]","[\"-\"]","[{\"name\":\"-\",\"logo\":\"https://toscalepublic.s3.eu-west-2.amazonaws.com/images/protocols/-.png\"}]","33",[],[],"https://toscalepublic.s3.eu-west-2.amazonaws.com/images/news-feeds/sources/market-beat.png","Market Beat",null,"","[\"Finance\"]","0","EN","1"]